Subretinal saline injection added to vitrectomy for diabetic macular edema with hard exudates
This randomized controlled trial enrolled 56 patients with diabetic macular edema and hard exudates. The intervention group received pars plana vitrectomy with internal limiting membrane peeling plus a subretinal injection of balanced salt solution, while the control group received vitrectomy and peeling alone. The mean follow-up was 7.13 ± 2.02 months.
Within the injection group, best-corrected visual acuity (Snellen) improved from 20/426 ± 20/98 to 20/163 ± 20/59 (P < 0.001). Central macular thickness decreased from 453.32 ± 125.90 µm to 305.14 ± 119.23 µm (P < 0.001). The hard exudates area decreased from 3.00 ± 1.68 mm² to 1.50 ± 1.24 mm² (P < 0.001). The foveal avascular zone area decreased from 0.41 ± 0.11 mm² to 0.32 ± 0.11 mm² (P < 0.001), and mean macular thickness decreased from 411.77 ± 64.52 µm to 322.96 ± 52.62 µm (P < 0.001). All reported P-values are for within-group changes.
Postoperative complications did not differ between groups (P > 0.05). Adverse events, serious adverse events, and discontinuation rates were not reported. Key limitations include the lack of a specified primary outcome, the absence of reported effect sizes or confidence intervals for between-group comparisons, and a short-term follow-up of approximately 7 months. The trial's small size (56 patients) and unreported funding or conflicts of interest are also notable.
For clinical practice, this single, small RCT suggests a potential association between adding a subretinal saline injection to vitrectomy and anatomical improvements in a specific DME subgroup. However, the evidence is insufficient to establish superiority over standard surgery due to the lack of direct between-group statistical comparisons and long-term data. The procedure's safety profile beyond immediate postoperative complications remains unclear.